RxDoctor Payments Data

Guy Wells, MD

Cardiovascular Disease · Lubbock, TXNPI 1891785887

Payments from drug & device makers

$4,607in general payments, 2019–2025

Across 180 payments — averaging $25.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$601
  • Boehringer Ingelheim$435
  • Novartis$385
  • E.r. Squibb & Sons, L.L.C.$330
  • Johnson & Johnson$318
  • AbbVie$270
  • plus $2K from 19 others

What the payments were for

  • Travel & lodging$60113%
  • Food & beverage$3,89585%
  • Education$1102%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,607 in reported general payments places this provider in the 55th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$182,306
Medicare patients
557
Services billed
2,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban149$152,008
XareltoRivaroxaban107$114,532
MultaqDronedarone Hcl21$29,916
BrilintaTicagrelor36$29,793
Repatha SureclickEvolocumab44$27,641
EntrestoSacubitril/Valsartan35$27,094
JardianceEmpagliflozin11$18,550
Metoprolol Succinate401$6,671
Amiodarone Hcl286$4,896
ClopidogrelClopidogrel Bisulfate364$3,601
Ranolazine ErRanolazine26$3,300
Potassium Chloride154$2,848
Diltiazem 24hr Er (Cd)Diltiazem Hcl88$2,659
Atorvastatin Calcium263$2,545
Isosorbide Dinitrate54$2,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$212$152,008149 claims
Johnson & JohnsonXarelto$318$114,532107 claims
AstraZenecaBrilinta$200$29,79336 claims
NovartisEntresto$385$27,09435 claims
Boehringer IngelheimJardiance$435$18,55011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →